Last $3.39 USD
Change Today +0.12 / 3.67%
Volume 293.4K
NBS On Other Exchanges
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

neostem inc (NBS) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/3/14 - $8.29
52 Week Low
12/12/14 - $3.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOSTEM INC (NBS)

Related News

No related news articles were found.

neostem inc (NBS) Related Businessweek News

No Related Businessweek News Found

neostem inc (NBS) Details

NeoStem, Inc., a biotechnology company, develops cell based therapeutics. It is developing a Phase III targeted cancer immunotherapy product to enhance the destruction of cancer initiating cells; a Phase II ischemic repair product candidate to treat damaged heart muscle following a heart attack; a Phase II immune modulation product candidate to treat type 1 diabetes and steroid resistant asthma; and an investigational technology to repair or replace damaged or aged tissue, cells, and organs. The company, through its subsidiary, Progenitor Cell Therapy, offers contract development and manufacturing services. It also collects, processes, and stores umbilical cord blood units and adult stem cells. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.

108 Employees
Last Reported Date: 03/13/14
Founded in 1980

neostem inc (NBS) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $945.0K
Chief Financial Officer
Total Annual Compensation: $190.6K
Chief Scientific Officer, President of Progen...
Total Annual Compensation: $494.2K
Chief Visionary Officer, Director, Chief Scie...
Total Annual Compensation: $586.5K
Chief Medical Officer
Total Annual Compensation: $331.5K
Compensation as of Fiscal Year 2013.

neostem inc (NBS) Key Developments

Neostem, Inc. Presents Results of Lovo(R) Cell Processing System Data

NeoStem, Inc. announced that it has presented results of PCT's most recent study to generate data on the performance of the Lovo Cell Processing System. The Lovo cell processor, developed and sold by Fresenius Kabi, is an automated system that removes supernatant from target cells and stores them in viable media. Lovo automates the labor-intensive tasks of separation, washing, platelet-reduction, fluid-exchange, and concentration of white blood cells. The system includes single-use disposable processing sets with a sterile fluid path to facilitate closed system processing. Fresenius Kabi introduced the Lovo system at the 20th Annual International Society for Cell Therapy meeting held in Paris, France in April 2014. The system is designed for use in research and transplant laboratories in academic institutions, biotech companies and other facilities that process cells. Utilizing its more than 15 years of cell processing expertise, PCT has been evaluating the use of the Lovo system in typical cell therapy applications and generating data on the operation, performance, and usability of the device. Study results presented at IBC indicate performance advantages of the Lovo system in comparison to other methods for cell washing and volume reduction, including high cell recovery, maintenance of cell viability, and effective reduction of pre-wash ingredients. The Lovo system also provided operational advantages, including closed, fully automated execution of the process. The data was generated for washing two liters of culture-expanded T cells into a final volume of 150 mL, a typical need for cellular immunotherapy applications. The study took place in PCT's Mountain View, California facility. PCT's collaboration in support of the Lovo system is one of the initiatives being undertaken by PCT's recently formed Engineering & Innovation Center (EIC), designed to help PCT's client base accelerate the development of more cost effective and robust manufacturing processes for cellular therapeutic candidates. Through the EIC, PCT helps its clients think beyond current practices and accelerate the use of automation, integration and other engineering strategies to address important issues such as scale up and cost of goods in anticipation of commercial production.

Neostem, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 02:30 PM

Neostem, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 02:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Douglas W. Losordo, Chief Medical Officer, Robin L. Smith, Executive Chairman and Chief Executive Officer.

Neostem, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 10:20 AM

Neostem, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 10:20 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Robin L. Smith, Executive Chairman and Chief Executive Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $3.39 USD +0.12

NBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.30 USD 0.00
Cesca Therapeutics Inc $1.08 USD -0.05
Cytori Therapeutics Inc $0.50 USD +0.0201
Nuo Therapeutics Inc $0.34 USD +0.0101
Vericel Corp $2.99 USD +0.12
View Industry Companies

Industry Analysis


Industry Average

Valuation NBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.1x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at